844 related articles for article (PubMed ID: 33783099)
1. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Klebanov N; Pahalyants V; Murphy WS; Theodosakis N; Zubiri L; Klevens RM; Kwatra SG; Lilly E; Reynolds KL; Semenov YR
Oncologist; 2021 May; 26(5):e898-e901. PubMed ID: 33783099
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
Mandala M; Lorigan P; De Luca M; Bianchetti A; Merelli B; Bettini AC; Bonomi L; Nahm S; Vitale MG; Negrini G; Di Croce A; Ascierto PA; Rulli E; Tondini CA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593827
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
4. Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
Luo B; Li J; Hou X; Yang Q; Zhou Y; Ye J; Wu X; Feng Y; Hu T; Xu Z; He Y; Sun J
Future Oncol; 2021 Sep; 17(26):3477-3484. PubMed ID: 34189948
[TBL] [Abstract][Full Text] [Related]
5. Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
Tan R; Yun C; Seetasith A; Sheinson D; Walls R; Ngwa I; Reddy JC; Zhang Q; Secrest MH; Lambert P; Sarsour K
Oncologist; 2022 Mar; 27(3):236-243. PubMed ID: 35274714
[TBL] [Abstract][Full Text] [Related]
6. Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists.
Ottaviano M; Curvietto M; Rescigno P; Tortora M; Palmieri G; Giannarelli D; Aieta M; Assalone P; Attademo L; Avallone A; Bloise F; Bosso D; Borzillo V; Buono G; Calderoni G; Caputo F; Cartenì G; Cavallero D; Cavo A; Ciardiello F; Conca R; Conteduca V; De Falco S; De Felice M; De Laurentiis M; De Placido P; De Placido S; De Santo I; De Stefano A; Della Corte CM; Di Franco R; Di Lauro V; Fabbrocini A; Federico P; Festino L; Giordano P; Giuliano M; Gridelli C; Grimaldi AM; Lia M; Marretta AL; Massa V; Mennitto A; Merler S; Merz V; Messina C; Messina M; Milano M; Minisini AM; Montesarchio V; Morabito A; Morgillo F; Mucci B; Nappi L; Napolitano F; Paciolla I; Pagliuca M; Palmieri G; Parola S; Pepe S; Petrillo A; Piantedosi F; Piccin L; Picozzi F; Pietroluongo E; Pignata S; Prati V; Riccio V; Rosanova M; Rossi A; Russo A; Salati M; Santabarbara G; Sbrana A; Simeone E; Silvestri A; Spada M; Tarantino P; Taveggia P; Tomei F; Vincenzo T; Trapani D; Trojanello C; Vanella V; Vari S; Ventriglia J; Vitale MG; Vitiello F; Vivaldi C; von Arx C; Zacchi F; Zampiva I; Zivi A; Daniele B; Ascierto PA;
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060148
[TBL] [Abstract][Full Text] [Related]
7. Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review.
Spagnolo F; Boutros A; Croce E; Cecchi F; Arecco L; Tanda E; Pronzato P; Lambertini M
Eur J Clin Invest; 2021 Jul; 51(7):e13604. PubMed ID: 34021591
[TBL] [Abstract][Full Text] [Related]
8. Impact of COVID-19 on Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Bui AN; Tyan K; Giobbie-Hurder A; Klein IA; Manos MP; Zubiri L; Reynolds K; Grover S; Weinhouse GL; Ott PA; LeBoeuf NR; Rahma O
J Immunother Precis Oncol; 2021 May; 4(2):35-44. PubMed ID: 35663537
[TBL] [Abstract][Full Text] [Related]
9. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
10. Management of immune checkpoint therapy for patients with cancer in the face of COVID-19.
Shen C; Li Q; Wei Y; Li Y; Li J; Tao J
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33303577
[TBL] [Abstract][Full Text] [Related]
11. Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.
Liu Y; Liu S; Qin Y; Zhao L; Li Y; Zhou C; Chen W
Int Immunopharmacol; 2021 Dec; 101(Pt A):108242. PubMed ID: 34688136
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors.
Szabados B; Abu-Ghanem Y; Grant M; Choy J; Bex A; Powles T
Eur Urol; 2020 Aug; 78(2):276-280. PubMed ID: 32534910
[TBL] [Abstract][Full Text] [Related]
13. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
14. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis.
Qian W; Ye Y; Zuo L; Song T; Xu Q; Wang Y; Qian J; Tian Y
Immunotherapy; 2021 Oct; 13(15):1271-1282. PubMed ID: 34431319
[TBL] [Abstract][Full Text] [Related]
16. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Mostaghim A; Minkove S; Aguilar-Company J; Ruiz-Camps I; Eremiev-Eremiev S; Dettorre GM; Fox L; Tondini C; Brunet J; Carmona-García M; Lambertini M; Bower M; Newsom-Davis T; Sharkey R; Pria AD; Rossi M; Plaja A; Salazar R; Sureda A; Prat A; Michalarea V; Van Hemelrijck M; Sita-Lumsden A; Bertuzzi A; Rimassa L; Rossi S; Rizzo G; Pedrazzoli P; Lee AJ; Murphy C; Belessiotis K; Diamantis N; Mukherjee U; Pommeret F; Stoclin A; Martinez-Vila C; Bruna R; Gaidano G; D'Avanzo F; Gennari A; Athale J; Eichacker P; Pinato DJ; Torabi-Parizi P; Cortellini A;
Int J Infect Dis; 2024 Feb; 139():13-20. PubMed ID: 38029831
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.
Minkove SJ; Sun J; Li Y; Cui X; Cooper D; Eichacker PQ; Torabi-Parizi P
Rev Med Virol; 2022 Sep; 32(5):e2352. PubMed ID: 35416370
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry.
Rüthrich MM; Giessen-Jung C; Borgmann S; Classen AY; Dolff S; Grüner B; Hanses F; Isberner N; Köhler P; Lanznaster J; Merle U; Nadalin S; Piepel C; Schneider J; Schons M; Strauss R; Tometten L; Vehreschild JJ; von Lilienfeld-Toal M; Beutel G; Wille K;
Ann Hematol; 2021 Feb; 100(2):383-393. PubMed ID: 33159569
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
Yatim N; Boussier J; Tetu P; Smith N; Bruel T; Charbit B; Barnabei L; Corneau A; Da Meda L; Allayous C; Baroudjian B; Jebali M; Herms F; Grzelak L; Staropoli I; Calmettes V; Hadjadj J; Peyrony O; Cassius C; LeGoff J; Kramkimel N; Aractingi S; Fontes M; Blanc C; Rieux-Laucat F; Schwartz O; Terrier B; Duffy D; Lebbé C
Sci Adv; 2021 Aug; 7(34):. PubMed ID: 34407944
[TBL] [Abstract][Full Text] [Related]
20. Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
Abid MB
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
